--- a
+++ b/clusters/9knumclustersv2/clust_1311.txt
@@ -0,0 +1,31 @@
+Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis, but not including hypothyroidism or psoriasis if condition has been stable for  months or greater
+History of auto-immune disease (e.g., thyroiditis, lupus), except vitiligo
+No active auto-immune disease and not on therapy for auto-immune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients who have adrenal insufficiency and hypophysitis from prior immunotherapy if they are on stable medical replacement doses are eligible
+Life expectancy of >  months (exclusive of the disease for which the auto HSCT is being performed)
+Active auto-immune disease including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
+Have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
+The subject has a history of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of:\r\n* Vitiligo
+Patients with auto-immune disease, with the exception of type I diabetes or treated hypothyroidism.
+Significant auto-immune disease requiring hospitalization within the past two years or any history of life-threatening auto-immune disease
+Subjects must not have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of auto-immune disease requiring steroid maintenance, or history of primary immunodeficiency
+Prior auto-immune disease
+Active autoimmune or auto-inflammatory ocular disease within  months
+History of auto-immune disease per physician discretion
+The subject has a history of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of: vitiligo, diabetes or thyroid dysfunction
+Patients with active auto-immune disease requiring immunosuppressive medication
+Auto-immune hemolytic anemia
+Ongoing clinically significant anemia due to factors such as iron, vitamin B, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal bleeding.
+Patients with active neurological auto immune or inflammatory disorders(e.g. Guillain Barre Syndrome, Amyptrophic Lateral Sclerosis)
+History of auto-immune disease
+Patients with known auto-immune disease
+Subject who has active auto-immune disease.
+Active auto-immune disease
+Auto-immune disease
+Decompensated liver disease (Child-Pugh score > ) or active or past auto-immune hepatitis
+Active known auto-immune disease with the exception of autoimmune thyroiditis, vitiligo, and alopecia;
+Patients with history of autoimmune disease (excluding thyroiditis on chronic thyroid replacement therapy) or active auto-immune disease, due to a risk of exacerbation of autoimmunity with r-hIL; patients with a history of B cell malignancy due to a risk for growth with rhIL therapy
+Subject has significant auto-immune disease
+Subjects with active auto immune disorders/processes or active neurological or inflammatory disorders
+Significant auto-immune disease requiring hospitalization within the past two years or any history of life-threatening auto-immune disease
+Auto-immune disease, which: